Patients with high PAX7 levels in breast cancer had a significantly worse prognosis compared to those with low PAX7 levels, as indicated by the overall survival results (hazard ratio [HR] 1.46 (1.05–2.02); p = 0.023) (Figure 2B). This evidence concerns the gene PAX7 and breast cancer.